The main protease (Mpro) is a key enzyme of SARS-CoV-2 and is required for viral replication and transcription.
A Biosynth Case Study
COVID-19, caused by SARS-CoV-2, currently lacks effective therapeutics. SARS-CoV-2 main protease (Mpro) represents an attractive drug target.
SARS-CoV-2 main protease Application Notes
Mpro activates the viral replicase by digesting replicase polyproteins at 11 conserved cleavage sites.
Cleavage occurs at the C-terminal end of glutamine in recognition sequences containing Leu-Gln-(Ser, Ala, Gly) motifs]. As SARS-CoV-2 Mpro has no closely related homologues in humans, it represents an attractive drug target. In addition, SARS-CoV-2 Mpro may be used for diagnostic purposes and for in vitro research on viral replication.
To read the full .pdf case study please complete the download form or contact Biosynth today.
Download the full case study